Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.

Molecular cancer therapeutics - 1 Mar 2020

Ye Song, Hu Xiaoge, Ni Chao, Jin Weiwei, Xu Yaping, Chang Lianpeng, Zhou Huaixiang, Jiang Jiahong, Yang Liu

Abstract excerpt

With the increase of treatment course, resistance to EGFR blockade is inevitable in patients with metastatic colorectal cancer (mCRC). KRAS mutations have been considered to be primary drivers of this resistance; however, the potential function of other genes has not been extensively investigated. This study collected 17 plasma samples from patients with mCRC with cetuximab resistance, and target-capture deep...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Kruppel-Like Factor 4

Share to Kruppel-Like Transcription Factors

Share to Survival Rate

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 31924740
DOI: 10.1158/1535-7163.MCT-18-1385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.PMID 31924740Read ↗

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.Semantic proximity Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.